Phase 1: Case Filing and MDL Enrollment
The first step for a PowerPort plaintiff is filing a complaint in federal court — in any federal district — and serving it on Becton Dickinson. The case is then transferred to MDL 3:22-md-03062 in the District of Arizona by the JPML. Within the MDL, each plaintiff completes a Plaintiff Fact Sheet (PFS) within the deadline set by the court's Case Management Order. The PFS asks detailed questions about the device implantation, medical history, fracture discovery, imaging findings, treatment, and economic losses. Providing complete, accurate, and well-documented PFS responses is critical — deficiencies can result in the case being placed on a delinquency list or dismissed. Your attorney handles PFS preparation and submission.
Phase 2: Discovery — Documents and Depositions
MDL discovery involves two parallel tracks. Common discovery — conducted by the PSC on behalf of all plaintiffs — addresses BD's internal documents: materials science testing of the polyurethane catheter, adverse event reports, regulatory submissions, communications between engineering and legal teams, and post-market surveillance data. Individual discovery — specific to individual plaintiffs' cases — involves obtaining each plaintiff's medical records, device records, and identifying treating physician witnesses. Common discovery depositions of BD corporate witnesses (engineers, regulatory affairs personnel, marketing executives) are conducted once but available to all plaintiffs. General causation expert reports — addressing whether the PowerPort polyurethane catheter can cause the alleged injuries — are disclosed and challenged through Daubert motions heard by the MDL judge.
Phase 3: Bellwether Trials and Settlement Pressure
Bellwether trials are the engine of MDL settlements. The court selects a pool of representative cases — chosen to reflect the range of injury severity, causation theories, and plaintiff demographics in the MDL — and schedules them for trial before the MDL judge or remand to their home districts. Bellwether verdicts, whether plaintiff or defense wins, provide both sides with concrete data about jury receptivity to the liability and damages evidence. Favorable plaintiff verdicts increase settlement pressure on BD and generate momentum toward global settlement negotiations. Unfavorable verdicts may prompt plaintiffs to accept lower settlement offers.
Phase 4: Global Settlement and Individual Compensation
Following successful bellwether trials, global settlement negotiations begin between BD and the PSC. A global settlement establishes a total fund and a points-based or grid-based allocation system that assigns individual settlement amounts based on injury severity tier, age at injury, economic losses, and other factors. Each individual plaintiff receives a settlement offer based on their position on the allocation grid. The claims administrator — an independent entity appointed to administer the settlement fund — reviews each plaintiff's documentation to verify the injury tier and calculate the individual payment.
Plaintiffs who accept the global settlement sign a release of all claims against BD and Bard in exchange for their individual payment. Plaintiffs who reject the settlement may pursue their cases individually — either in the MDL or remanded to their home district for trial. The vast majority of plaintiffs accept global settlements because they provide a certain recovery without the risk and delay of individual trial. Payments are typically made within 6 to 12 months of settlement acceptance after the claims administrator completes the documentation review process. Your attorney will advise you on whether the settlement offer for your specific case is fair given your injuries and circumstances.
Frequently Asked Questions
Related Pages
PowerPort Catheter Fracture — How It Happens
Bard PowerPort catheters fracture through a well-documented mechanism called environmental stress cracking (ESC) of polyurethane — a process that was scientifically foreseeable at the time of device design. The fracture is silent and painless, meaning most patients have no idea their catheter has broken until complications force diagnostic imaging.
PowerPort Catheter Migration — Where Fragments Go
When a PowerPort catheter fractures, the free fragment enters the central venous circulation and travels to the heart and lungs following the path of venous blood flow. The fragment's final resting location determines the severity of injury — from retrievable right-heart positions to life-threatening peripheral pulmonary artery lodgment.
Bard PowerPort MDL in the District of Arizona
MDL No. 3:22-md-03062 in the U.S. District Court for the District of Arizona is the central federal forum for all Bard PowerPort catheter fracture cases. Understanding how the MDL works, where it currently stands, and what participation means for individual plaintiffs is essential for anyone considering a PowerPort lawsuit.
PowerPort vs. Other Port Catheters — Key Differences
The Bard PowerPort's polyurethane catheter is the defining design characteristic that distinguishes it from safer alternatives like Hickman catheters, silicone Mediport devices, and PICC lines — none of which use polyurethane tubing and none of which carry the same environmental stress cracking fracture risk.
PowerPort Removal Surgery — How Fractured Catheters Are Retrieved
Retrieval of a fractured PowerPort catheter fragment requires either percutaneous cardiac catheterization or open thoracic surgery, depending on fragment location and accessibility. The retrieval procedure itself carries procedural risks, and failure to retrieve leaves the patient with an ongoing foreign body infection and cardiac risk.
PowerPort Sepsis and Infection Risk
A fractured PowerPort catheter fragment acts as a permanent intravascular nidus for infection — a foreign body that bacteria colonize with a protective biofilm that antibiotics cannot eradicate without removing the fragment. For immunocompromised cancer patients, this infection risk is particularly life-threatening.
PowerPort Cardiac Perforation — Heart Surgery Risk
Cardiac perforation by a fractured PowerPort catheter fragment is a life-threatening emergency. The thin-walled right ventricle is particularly vulnerable to penetration by a fragment's sharp edge, causing cardiac tamponade — a surgical emergency that can be fatal within minutes without treatment.
Becton Dickinson Liability — BD's Acquisition of Bard
Becton, Dickinson and Company (BD) acquired C.R. Bard in 2017 for $24 billion and assumed full corporate liability for all Bard product claims, including the PowerPort. BD now faces claims not only for Bard's pre-acquisition conduct but also for BD's own post-acquisition decisions to continue selling the PowerPort without redesigning or adequately warning about the fracture risk.
PowerPort Evidence and Records — What You Need for Your Case
Building a strong PowerPort catheter lawsuit requires gathering specific categories of medical and device records. Even if you no longer have the physical device, documentary evidence of the fracture, fragment location, and resulting injury is sufficient to support a claim.
Bard PowerPort Catheter Lawsuit
The Bard PowerPort is an implantable venous access device — a small port placed under the skin, typically in the chest — that allows medical professionals to administer chemotherapy, draw blood, and deliver medications without repeated needle sticks. Millions of patients have received PowerPort devices since C.R. Bard introduced them in the 1990s. The devices are especially common among cancer patients who require long-term intravenous access. Beginning in the early 2010s, patients, physicians, and researchers began documenting a disturbing pattern: the polyurethane catheter tubing attached to the port was fracturing inside the body. Fragments of the catheter — sometimes several centimeters long — were entering the bloodstream and migrating toward the heart and lungs. The resulting complications range from serious to fatal: cardiac perforation, cardiac tamponade, pulmonary embolism, sepsis, and endocarditis. Becton Dickinson (BD) acquired C.R. Bard in 2017 for $24 billion, inheriting both the PowerPort product line and the mounting litigation. In 2022, a federal multidistrict litigation was established in the U.S. District Court for the District of Arizona to consolidate cases nationwide. Legal claims proceed under theories of design defect, manufacturing defect, failure to warn, and negligence. Patients who received a PowerPort catheter and subsequently experienced catheter fracture, fragment migration, infection, cardiac complications, or unexplained symptoms may be entitled to substantial compensation.
View full case overview